Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8071 to 8085 of 8940 results

  1. Heart failure (acute decompensated) - nesiritide [ID384]

    Discontinued Reference number: GID-TAG376

    Technology appraisal guidance
    Discontinued

  2. Atrial fibrillation - ximelagatran [ID376]

    Discontinued Reference number: GID-TAG377

    Technology appraisal guidance
    Discontinued

  3. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued Reference number: GID-TAG378

    Technology appraisal guidance
    Discontinued

  4. Prostate cancer (hormone refractory) - atrasentan [ID390]

    Discontinued Reference number: GID-TAG379

    Technology appraisal guidance
    Discontinued

  5. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued Reference number: GID-TAG382

    Technology appraisal guidance
    Discontinued

  6. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued Reference number: GID-TAG383

    Technology appraisal guidance
    Discontinued

  7. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued Reference number: GID-TAG384

    Technology appraisal guidance
    Discontinued

  8. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued Reference number: GID-TAG385

    Technology appraisal guidance
    Discontinued

  9. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued Reference number: GID-TAG387

    Technology appraisal guidance
    Discontinued

  10. Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

    In development Reference number: GID-TAG388 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]

    In development Reference number: GID-TA11781 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Digital technologies for multidisciplinary weight management

    In development Reference number: GID-HTE10077 Expected publication date: TBC

    Health technology evaluations
    In development

  13. Digital technologies to support smoking cessation in secondary care patients: early value assessment

    In development Reference number: GID-HTE10061 Expected publication date: TBC

    Health technology evaluations
    In development

  14. Superior rectal artery embolisation for haemorrhoids

    Discontinued Reference number: GID-IPG10417

    Interventional procedures guidance
    Discontinued

  15. Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]

    In development Reference number: GID-TA11800 Expected publication date: TBC

    Technology appraisal guidance
    In development